Comparison of BCR-ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

被引:4
|
作者
Sales, Livia De Oliveira [1 ]
Mesquita, Felipe Pantoja [2 ]
De Sousa Portilho, Adrhyann Jullyanne [2 ]
De Moraes Filho, Manoel Odorico [2 ]
Amaral De Moraes, Maria Elisabete [2 ]
Montenegro, Raquel Carvalho [2 ]
Moreira-Nunes, Caroline Aquino [1 ,2 ]
机构
[1] Christus Univ Ctr Unichristus, Fac Biomed, Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara, Drug Res & Dev Ctr NPDM, Dept Physiol & Pharmacol, Pharmacogenet Lab, Fortaleza, Ceara, Brazil
来源
IN VIVO | 2019年 / 33卷 / 04期
关键词
CML; leukaemia; BCR-ABL; cell lines; MULTIDRUG-RESISTANCE; IMATINIB MESYLATE; MOLECULAR-BIOLOGY; CML; EXPRESSION; E13A2;
D O I
10.21873/invivo.11581
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/aim: Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the presence of breakpoint cluster region-Abelson murine leukemia (BCR-ABL1) gene fusion as a hallmark that is expressed as two major transcripts b2a2 and b3a2. The aim of this study was to compare the BCR-ABL transcripts in the blood cells of patients with CML, and in chemoresistant and chemosensitive CML cell lines to validate their use as a good method to elucidate CML biology. Materials and Methods: Twelve patients with CML and CML cell lines (K562, K562-LUCENA and FEPS) were analyzed by real-time polymerase chain reaction to evaluate gene expression of BCR-ABL transcripts. Results: All patients had the same expression levels of b2a2 and b3a3 transcripts, however, CML cell lines presented only b3a2 expression. There were no significant differences in absolute b3a2 expression between patients and CML cell lines. Conclusion: CML cell lines provide a good in vitro alternative in that they have the same BCR-ABL expression as patients.
引用
收藏
页码:1119 / 1124
页数:6
相关论文
共 50 条
  • [31] Upregulation of the TGFβ signalling pathway by Bcr-Abl:: Implications for haemopoietic cell growth and chronic myeloid leukaemia
    Moller, Gigi M. O.
    Frost, Victoria
    Melo, Junia V.
    Chantry, Andrew
    FEBS LETTERS, 2007, 581 (07) : 1329 - 1334
  • [32] T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association
    Faizan, Mahwish
    Anwar, Saadia
    Ul Ain, Rahat
    Zafar, Huma
    Saqlain, Nazish
    Rathore, Zunaira
    ECANCERMEDICALSCIENCE, 2021, 15
  • [33] Antisense oligonucleotides targeting BCR-ABL for purging autografts in chronic myeloid leukaemia.
    Clark, RE
    Spiller, DG
    Broughton, CM
    Grzybowski, J
    Pender, N
    Brammer, C
    Tidd, DM
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 91 - 91
  • [34] LONG TERM RESULTS WITH TYROSINE KINASE INHIBITORS BCR-ABL IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE
    Nunnz Yizel, Paz
    Gabriela, Silva Carreras F.
    Victoria, Vaitsekhovich
    Cecile, Mba
    Navascues Javier, Cornago
    Juan Luis, Steegmann Olmedillas
    HAEMATOLOGICA, 2016, 101 : 176 - 176
  • [35] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
    O'Connor, Lisa M.
    Langabeer, Stephen
    McCann, Shaun R.
    Conneally, Eibhlin
    BLOOD, 2007, 110 (11) : 699A - 700A
  • [36] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
    S Branford
    N C P Cross
    A Hochhaus
    J Radich
    G Saglio
    J Kaeda
    J Goldman
    T Hughes
    Leukemia, 2006, 20 : 1925 - 1930
  • [37] The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia
    Jeffs, AR
    Benjes, SM
    Smith, TL
    Sowerby, SJ
    Morris, CM
    HUMAN MOLECULAR GENETICS, 1998, 7 (05) : 767 - 776
  • [38] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
    Branford, S.
    Cross, N. C. P.
    Hochhaus, A.
    Radich, J.
    Saglio, G.
    Kaeda, J.
    Goldman, J.
    Hughes, T.
    LEUKEMIA, 2006, 20 (11) : 1925 - 1930
  • [39] Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib
    Wang, L
    Butt, NM
    Atherton, MG
    Clark, RE
    LEUKEMIA, 2004, 18 (05) : 1025 - 1027
  • [40] BCR-ABL peptide boost vaccinations can maintain anti-BCR-ABL immune responses in chronic myeloid leukaemia (CML) patients
    Rojas, J. M.
    Knight, K.
    Watmough, S.
    Bell, J.
    Wang, L. H.
    Clark, R. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 63 - 63